Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
Ute Hennrich, Matthias Eder
Pharmaceuticals (2022) Vol. 15, Iss. 10, pp. 1292-1292
Open Access | Times Cited: 148

Showing 1-25 of 148 citing articles:

Urease-powered nanobots for radionuclide bladder cancer therapy
Cristina Simó, Meritxell Serra-Casablancas, Ana C. Hortelão, et al.
Nature Nanotechnology (2024) Vol. 19, Iss. 4, pp. 554-564
Open Access | Times Cited: 60
Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions
Nguyễn Thị Thanh Nhàn, Tohru Yamada, Kaori Yamada
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12931-12931
Open Access | Times Cited: 55
Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides
Katherine A. Morgan, Stacey E. Rudd, Asif Noor, et al.
Chemical Reviews (2023) Vol. 123, Iss. 20, pp. 12004-12035
Closed Access | Times Cited: 43
Radiotheranostics Global Market and Future Developments
Akram Al‐Ibraheem, Richard Zimmermann, Ahmed Saad Abdlkadir, et al.
Seminars in Nuclear Medicine (2024) Vol. 54, Iss. 4, pp. 622-633
Closed Access | Times Cited: 22
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617
Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, et al.
Theranostics (2024) Vol. 14, Iss. 5, pp. 1829-1840
Open Access | Times Cited: 17
Radiopharmaceuticals and their applications in medicine
Siqi Zhang, Xingkai Wang, Xin Gao, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Dual-Labeled Small Peptides in Cancer Imaging and Fluorescence-Guided Surgery: Progress and Future Perspectives
Patrick G. Minges, Matthias Eder, Ann-Christin Eder
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 143-143
Open Access | Times Cited: 2
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Youlong Du, Anas Semghouli, Qian Wang, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 1
Open Access | Times Cited: 2
Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies
Andrea Monti Hughes, Naonori Hu
Cancers (2023) Vol. 15, Iss. 16, pp. 4091-4091
Open Access | Times Cited: 39
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
Kanchi Patell, Matthew Kurian, Jorge A. García, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 7, pp. 731-744
Open Access | Times Cited: 25
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
Xuejun Wen, Peng‐Fei Xu, Xinying Zeng, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 9, pp. 2846-2860
Closed Access | Times Cited: 24
Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside
Camille Van Laere, Michel Koole, Christophe M. Deroose, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1720-1743
Open Access | Times Cited: 17
Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma
Fanching Lin, Renee Clift, Takeru Ehara, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 4, pp. 586-592
Closed Access | Times Cited: 14
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
Salomon Tendler, Mark Dunphy, Matthew Agee, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 1015-1024
Closed Access | Times Cited: 13
Actinium-225 targeted alpha particle therapy for prostate cancer
Anil P. Bidkar, Luann Zerefa, Surekha Yadav, et al.
Theranostics (2024) Vol. 14, Iss. 7, pp. 2969-2992
Open Access | Times Cited: 11
Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases
Michael R. Dyer, Zhenghan Jing, Kathleen Duncan, et al.
Nuclear Medicine and Biology (2024) Vol. 130-131, pp. 108879-108879
Closed Access | Times Cited: 9
Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology
Zhongji Jiang, Gaohaer Kadeerhan, Jin Zhang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
Philipp Ritt, René Fernández, Cristian Soza‐Ried, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Open Access | Times Cited: 1
Current Advances in PARP1‐Targeted Theranostics
Jie Tong, Baosheng Chen, Tommaso Volpi, et al.
Journal of Labelled Compounds and Radiopharmaceuticals (2025) Vol. 68, Iss. 1-2
Closed Access | Times Cited: 1
Radiolysis-Associated Decrease in Radiochemical Purity of 177Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process
А. А. Ларенков, Yu. A. Mitrofanov, Ekaterina Pavlenko, et al.
Molecules (2023) Vol. 28, Iss. 4, pp. 1884-1884
Open Access | Times Cited: 18
Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics
Shohei Tsuchihashi, Kazuma Nakashima, Yuta Tarumizu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8043-8053
Closed Access | Times Cited: 17
PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer
Anubhav Dhull, Jing Wei, Anunay James Pulukuri, et al.
Nanoscale (2024) Vol. 16, Iss. 11, pp. 5634-5652
Closed Access | Times Cited: 7
Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
Yuanzhuo Yan, Huixian Zhuo, Tengfei Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
[ 68 Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer
Jessica Clore, Peter J. H. Scott
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 7, pp. 565-582
Closed Access | Times Cited: 7
Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer
Wenhao Zhou, Wei Zhang, Shi Yan, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 627-627
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top